SCPS (Scopus BioPharma) Ending Cash Position: $0.36 Mil (As of Jun. 2023)


What is Scopus BioPharma Ending Cash Position?

Scopus BioPharma SCPS Ending Cash Position is $0.36 Mil as of Jun. 2023.

Scopus BioPharma's Ending Cash Position for the quarter that ended in Jun. 2023 was $0.36 Mil.

Scopus BioPharma's quarterly Ending Cash Position increased from Dec. 2022 ($0.13 Mil) to Mar. 2023 ($1.40 Mil) but then declined from Mar. 2023 ($1.40 Mil) to Jun. 2023 ($0.36 Mil).

Scopus BioPharma's annual Ending Cash Position increased from Dec. 2020 ($1.83 Mil) to Dec. 2021 ($7.94 Mil) but then declined from Dec. 2021 ($7.94 Mil) to Dec. 2022 ($0.13 Mil).

Scopus BioPharma Ending Cash Position Related Terms

Scopus BioPharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Ending Cash Position Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Get a 7-Day Free Trial 0.00 0.04 1.83 7.94 0.13

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.31 0.13 1.40 0.36

Scopus BioPharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Scopus BioPharma's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.944+-7.819
=0.13

Scopus BioPharma's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.401+-1.039
=0.36

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.36 Mil mean?
Scopus BioPharma (SCPS) has a Ending Cash Position of $0.36 Mil as of Jun. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Ending Cash Position too high?
Scopus BioPharma's current Ending Cash Position is $0.36 Mil.
How does Scopus BioPharma's Ending Cash Position compare to AMPE and DRMA?
Scopus BioPharma's Ending Cash Position of $0.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Ending Cash Position is $0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Ending Cash Position of $0.36 Mil. The current Ending Cash Position is $0.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Ending Cash Position is $0.36 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.